Aryx Therapeutics I Stock Cash Per Share
ARYXDelisted Stock | USD 0.0005 0.00 0.00% |
Aryx Therapeutics I fundamentals help investors to digest information that contributes to Aryx Therapeutics' financial success or failures. It also enables traders to predict the movement of Aryx Pink Sheet. The fundamental analysis module provides a way to measure Aryx Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aryx Therapeutics pink sheet.
Aryx |
Aryx Therapeutics I Company Cash Per Share Analysis
Aryx Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Aryx Therapeutics Cash Per Share | 0.09 X |
Most of Aryx Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aryx Therapeutics I is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Aryx Therapeutics I has a Cash Per Share of 0.09 times. This is 97.93% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash per share for all United States stocks is 98.2% higher than that of the company.
Aryx Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aryx Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aryx Therapeutics could also be used in its relative valuation, which is a method of valuing Aryx Therapeutics by comparing valuation metrics of similar companies.Aryx Therapeutics is currently under evaluation in cash per share category among its peers.
Aryx Fundamentals
Return On Asset | -0.75 | ||||
Current Valuation | 237.58 K | ||||
Shares Outstanding | 33.46 M | ||||
Shares Owned By Institutions | 0.14 % | ||||
Number Of Shares Shorted | 89.05 K | ||||
Price To Book | 37.83 X | ||||
EBITDA | (14.18 M) | ||||
Net Income | (33.17 M) | ||||
Cash And Equivalents | 2.95 M | ||||
Cash Per Share | 0.09 X | ||||
Debt To Equity | (5.11) % | ||||
Current Ratio | 0.47 X | ||||
Book Value Per Share | (0.23) X | ||||
Cash Flow From Operations | (34.97 M) | ||||
Short Ratio | 0.79 X | ||||
Earnings Per Share | (0.59) X | ||||
Target Price | 1.5 | ||||
Number Of Employees | 56 | ||||
Beta | 0.0896 | ||||
Market Capitalization | 237.58 K | ||||
Total Asset | 12.41 M | ||||
Retained Earnings | (187.11 M) | ||||
Working Capital | 126 K | ||||
Current Asset | 8.62 M | ||||
Current Liabilities | 8.49 M | ||||
Z Score | -24.3 | ||||
Net Asset | 12.41 M |
About Aryx Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aryx Therapeutics I's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aryx Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aryx Therapeutics I based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Aryx Pink Sheet
If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |